Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma. - Wikidata - wikimedia - TriplyDB

Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma.

Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma.

http://www.wikidata.org/entity/Q42014659

about

Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)Myeloid-derived suppressor cells as therapeutic target in hematological malignancies Improving cancer immunotherapy by targeting the STATe of MDSCs The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression Novel therapeutic strategies for multiple myeloma Molecular pathways: myeloid complicity in cancer.Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma.Complexity and challenges in defining myeloid-derived suppressor cells Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells.The nitric oxide radical scavenger carboxy-PTIO reduces the immunosuppressive activity of myeloid-derived suppressor cells and potentiates the antitumor activity of adoptive cytotoxic T lymphocyte immunotherapy.Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors.Immunological dysregulation in multiple myeloma microenvironment.Myeloid-derived suppressor cells: their role in the pathophysiology of hematologic malignancies and potential as therapeutic targets.Targeting the bone marrow microenvironment in multiple myeloma.Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities.Highlights on mechanisms of drugs targeting MDSCs: providing a novel perspective on cancer treatment.Chimeric Antigen Receptor (CAR) therapy for multiple myeloma.The Role of Myeloid-Derived Suppressor Cells in Viral Infection.Role of the Immune Response in Disease Progression and Therapy in Multiple Myeloma.Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche.Myeloid-Derived Suppressor Cells.Identification of inhibitors of myeloid-derived suppressor cells activity through phenotypic chemical screening.Phosphodiesterase type 5 and cancers: progress and challenges.Immunotherapy of cancer: targeting cancer during active disease or during dormancy?Use of phosphodiesterase type 5 inhibitors and risk of melanoma: a meta-analysis of observational studies.Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents.Translational Potential of Therapeutics Targeting Regulatory Myeloid Cells in Tuberculosis Myeloid-Derived Suppressor Cells and Pulmonary Hypertension

P2860

Q26770391-2E4EA6BB-CBBB-4788-8E77-D4E9BAB27AF1 Q27010234-C07B10C6-5AAD-42CA-95F1-2126341D8461 Q28066797-5E0892FB-2821-484E-9743-500BFA287BBF Q28076760-C23EFE0F-E808-4DF4-871F-9D8EA316B94E Q28081590-0856816C-EAF2-48B8-A30A-760EF54214BE Q34725969-8648A7DE-E501-44AD-8FF6-5E1925877759 Q35087551-86E7E7A0-272F-4585-AE0E-B6FF5EAB5835 Q35509317-1BF9C2D4-E161-4A4C-9C02-39EB6CC9361F Q35833055-98B9A0B2-9890-4B87-AC8E-211172F25183 Q36060268-751CCC0F-432C-487C-817D-DA3C8A9D4D99 Q36447553-CA9D2054-CBFB-4D42-B094-12BB7FD03CB1 Q36557537-247E4E12-7D11-4881-A99D-1C9BE9673659 Q38228353-49953FE2-1F1C-4519-93BE-18078E38A1C0 Q38269370-D01FB835-10E1-465F-9781-D1639FAF0F79 Q38289041-8AE1DD37-8760-4D2C-AAD5-7960D4E577E9 Q38299932-248918C2-203D-4B3F-AE5D-44AB2B6F9E3E Q38398117-1F4CBA64-695F-40CD-8DFC-3E3C9C447365 Q38704573-90C52798-B542-4AD6-A375-1D6E871A53DE Q38774994-7F531311-60F1-422C-94FB-141D71022ABA Q38815399-41B7B0A7-6460-4999-BB71-46FB83D38108 Q38932298-22CF4DDE-029E-4A54-8D58-5DCC715F6562 Q40385399-19DCFBD7-E69E-47E5-AA70-F7F47DD60DBD Q45160017-624357DB-D9F4-4B70-AC48-0FCB4C3184E0 Q47171803-A925413A-942C-4A61-B7C8-8DFB8C339CCA Q47729557-02E8B31C-D713-43E0-9B17-47F40DC97684 Q49298466-376FBEFA-4DB6-4BBF-82BD-B3ED0741165B Q55247585-0D49436A-67DA-4702-A4DE-8751D83AC68A Q57299995-45DEC440-676A-4E75-BE32-A91C9F525580 Q58800964-FA3C7329-E1A6-4146-AC63-D010A4A8487B

P2860

Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma.

http://www.wikidata.org/entity/Q42014659

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma.

@en

Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma.

@nl

type

label

Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma.

@en

Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma.

@nl

prefLabel

Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma.

@en

Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma.

@nl

P1433

Q42014659-AE6DCB49-4A78-4A8F-B695-2C798808F492

P1476

Q42014659-0D8873F9-7B21-4C32-9481-9B60FCDDA89A

P2093

Q42014659-0A97A6AD-DCFB-4604-BC91-64D06F7C4169

Q42014659-19FA12CB-F6FB-45A5-BC34-97DD45476650

Q42014659-324DB310-BAA5-4CF6-A030-6B04F07A3B6E

Q42014659-A857F53D-34A2-4A40-B33C-C054A0C77CF3

Q42014659-E2199473-481F-4C3F-9D25-3050562FFED9

P2860

Q42014659-11334D0D-4DC7-41B2-A0C7-8DB173C58B3D

Q42014659-199C0EB4-5F58-4444-A640-186DEC731085

Q42014659-1D8C0B7D-72BB-42D4-968D-74BC5810B900

Q42014659-24D08986-6723-43AA-9042-75006E7A3EF5

Q42014659-3CCD3BFE-1F63-4221-8C66-BC52045904BB

Q42014659-694A0D0A-C56C-4918-9DEA-4C477868AA17

Q42014659-6C0E7B59-0A15-45E6-A4B3-933CA50488BA

Q42014659-7D38CA80-B627-4DD2-8FB0-AA2E8BBC6536

Q42014659-96E2A35F-6840-481A-B05C-2611A6F2A3E1

Q42014659-981FCD35-5FB9-4431-A5B7-AFEDD0F5B74E

P304

Q42014659-0D5FE12F-BD8B-474D-9908-FDD6091EC089

P31

Q42014659-6AA72C71-4D15-42BE-BEF4-2FCDCD55A807

P356

Q42014659-0C52D2AD-D431-43D2-A7FE-5E7E1CA40779

P433

Q42014659-A11FAC1A-F3B6-455E-8DC6-9D533D541A51

P478

Q42014659-7F82B534-68FD-42DA-8434-D02799517997

P577

Q42014659-A7858A16-E11F-4AA9-956A-3861FB807974

P5875

Q42014659-09502B2F-70ED-4AD4-9246-069B9D04CA0D

P698

Q42014659-98FAB68E-77B0-40F6-9075-B4313031795C

P932

Q42014659-02054838-D8DC-48A5-90A3-1DAF98FD4176

P356

2326-6066.CIR-13-0213

P1433

Cancer immunology research

P1476

Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma.

@en

P2093

Ivan Borrello

http://www.w3.org/2001/XMLSchema#string

Kimberly A Noonan

http://www.w3.org/2001/XMLSchema#string

Lakshmi Rudraraju

http://www.w3.org/2001/XMLSchema#string

Marilyn Bui

http://www.w3.org/2001/XMLSchema#string

Nilanjan Ghosh

http://www.w3.org/2001/XMLSchema#string

P2860

Myeloid-derived suppressor cells as regulators of the immune system

Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function

Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine.

Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells.

Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance.

Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells.

Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species.

Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells.

Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression.

Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer.

P304

725-731

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2326-6066.CIR-13-0213

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262786051

http://www.w3.org/2001/XMLSchema#string

P698

24878583

http://www.w3.org/2001/XMLSchema#string

P932

4152913

http://www.w3.org/2001/XMLSchema#string